← Back to all substances
C

simvastatin

226ms
Level 1

✓ What this shows

  • • Reported adverse events from FDA FAERS
  • • Descriptive statistics from a locked corpus
  • • Data verified with cryptographic hashes

✗ What this is NOT

  • • Not medical advice or recommendations
  • • Not proof of causality
  • • Not a complete safety profile

About this substance

Class: HMG-CoA Reductase Inhibitor [EPC], Dietary Cholesterol Absorption Inhibitor [EPC]

1 INDICATIONS AND USAGE Ezetimibe and simvastatin tablets Ezetimibe and simvastatin tablets are a combination of simvastatin and ezetimibe indicated: As an adjunct to diet to reduce elevated low density lipoprotein cholesterol (LDL-C): In adults with primary hyperlipidemia. In adults and pediatric p...

Known as: Ezetimibe and Simvastatin
Route: ORAL
Source: OpenFDA Drug Labels · Reference only · Not medical advice
500
Events in Corpus
v20260131-01
208,830
Total in FDA
78%
Serious Reports
35
Fatal Outcomes

Seriousness

Serious
391
Non-Serious
109

Sex Distribution

Male
212
Female
271
Unknown
17

Age Distribution

18-40
8
41-64
171
65-84
213
85+
20
Unknown
88

Outcomes

Recovered/Resolved
350
Recovering/Resolving
150
Not Recovered/Not Resolved
312
Recovered with Sequelae
42
Fatal
35
Unknown
864

Top Reported Reactions (click to view reports)

Verification Data

Corpus Version: v20260131-01
Root Hash: ec5727564d1ed19be5b08b26d3866f446b12d3d388f5a8cd713332c6d97ad264
Stats Hash: N/A
EVE Decision ID: EVE-MED-20260402-1e9191
ℹThis output reports adverse events from FDA FAERS. It does not constitute medical advice.

Molecular Structure (reference)

Structural visualization for identification only.

This visualization shows the molecular structure for identification purposes only. It does not represent pharmacological effect, safety, or clinical relevance.

Loading structure...